Sigma-Tau Pharmaceuticals, Inc. is a research-based pharmaceutical company focused
on the discovery of molecules and therapies to help improve the lives of people
who suffer from rare diseases.
This product information is intended for U.S. residents only. You should
not construe anything on this site as a promotion or solicitation for any product
or for the use of any product outside the United States.
|
Development Program
|
|
Indication
|
|
Development Stage
|
|
|
|
Defibrotide in severe Venous Occlusive Disease
|
|
Treatment of Hepatic venous occlusive disease after stem cell transplantation
|
|
NDA/Preparation
|
|
EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA])
|
|
For enzyme replacement therapy for adenosine deaminase (ADA) deficiency in patients
with severe combined immunodeficiency disease (SCID) who are not suitable candidates
for or who have failed bone marrow transplantation.
|
|
Phase III
|
|
EZN-2285 (calaspargase pegol)
|
|
Treatment of Acute Lymphoblastic Leukemia (ALL)
|
|
BLA/Preparation
|
|
Nuartez™ (artesunate) Injection in severe malaria
|
|
Immediate treatment of severe and complicated falciparum malaria
|
|
NDA/Preparation
|
|
STP-206 live biotherapeutic
|
|
Prevention of necrotizing enterocolitis (NEC)
|
|
Phase II
|
|
Xenbilox® (chenodeoxycholic acid) Capsules
|
|
Treatment of cerebrotendinous xanthomatosis (CTX)
|
|
NDA/Preparation
|
|
|
